Initial findings from the DREAM-GI national database: Assessing the efficacy and safety of neoadjuvant immunotherapy (NIT) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastrointestinal (GI) cancer
Recommended Citation
Chakrabarti S, Selfridge JE, Parish M, et al. Initial findings from the DREAM-GI national database: Assessing the efficacy and safety of neoadjuvant immunotherapy (NIT) in patients with deficient mismatch repair/microsatellite instability-high (dMMR/MSI-H) gastrointestinal (GI) cancer. Journal of Clinical Oncology. 2024/01/20 2024;42(3_suppl):736-736. doi:10.1200/JCO.2024.42.3_suppl.736
Type
Abstract